FindTrial
Sign In

Pharmacogenetic analyses to identify predators of efficacy and tolerability of Methotrexate by Crohn's disease patients

Pharmacogenetic analyses to identify predators of efficacy and tolerability of Methotrexate by Crohn's disease patients - MethoGen

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00009493
Enrollment
200
Registered
2015-10-12
Start date
2013-02-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K50.0 K50.1

Interventions

Group 1: - Crohn's disease patients with Methotrexate therapy - over 18 years old - blood sampling (20 ml) during the regular check-up

Sponsors

CED Service GmbH
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Crohn's disease patients with a previous Methotrexate therapy

Exclusion criteria

Exclusion criteria: no

Design outcomes

Primary

MeasureTime frame
Comparison of the Crohn's disease patients' pharmacogenetic profile with respond to Methotrexate versus non-respond to Methotrexate at 3d month—

Secondary

MeasureTime frame
1. Comparison of pharmacogenetic profile of Crohn’s disease patients in remission versus Crohn’s disease patients without remission at 3d month 2. Comparison of pharmacogenetic profile of Crohn’s disease patients in remission versus Crohn’s disease patients without respond at 3d month 3. Comparison of pharmacogenetic profile of Crohn’s disease patients tolerability versus side-effects at 3d month—

Countries

Germany

Contacts

Public ContactRaimonda Gettkowski

CED Service GmbHc/o GISG Organisationsbüro

r.gettkowski@gisg.eu0049 431 597 4153

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026